This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

BiomX Crescita futura

Future criteri di controllo 0/6

Si prevede che gli utili di BiomX diminuiranno del 15.7% all'anno, mentre si prevede che il fatturato annuo crescerà del 95.3% all'anno. Si prevede che l'EPS crescerà del 4% all'anno.

Informazioni chiave

-15.7%

Tasso di crescita degli utili

4.0%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.4%
Tasso di crescita dei ricavi	95.3%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	19 Sep 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

NYSEAM:PHGE.U - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	N/A	-45	N/A	N/A	2
12/31/2025	N/A	-39	N/A	34	2
12/31/2024	N/A	-30	N/A	32	2
6/30/2024	N/A	-26	-35	-35	N/A
3/31/2024	N/A	-34	-28	-28	N/A
12/31/2023	N/A	-26	-21	-21	N/A
9/30/2023	N/A	-27	-22	-22	N/A
6/30/2023	N/A	-25	-22	-22	N/A
3/31/2023	N/A	-27	-27	-27	N/A
12/31/2022	N/A	-28	-29	-29	N/A
9/30/2022	N/A	-33	-31	-31	N/A
6/30/2022	N/A	-36	-33	-31	N/A
3/31/2022	N/A	-36	-31	-29	N/A
12/31/2021	N/A	-36	-31	-28	N/A
9/30/2021	N/A	-35	-30	-26	N/A
6/30/2021	N/A	-34	-29	-26	N/A
3/31/2021	N/A	-33	-26	-24	N/A
12/31/2020	N/A	-30	-25	-24	N/A
9/30/2020	N/A	-27	-25	-24	N/A
6/30/2020	N/A	-23	-24	-23	N/A
3/31/2020	N/A	-22	-23	-21	N/A
12/31/2019	N/A	-21	-19	-18	N/A
9/30/2019	N/A	-22	-15	-14	N/A
6/30/2019	N/A	-19	-13	-12	N/A
3/31/2019	N/A	-17	-12	-12	N/A
12/31/2018	N/A	-15	-11	-11	N/A
12/31/2017	N/A	-7	N/A	-4	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che PHGE.U rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che PHGE.U rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che PHGE.U rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che PHGE.U non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che PHGE.U non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di PHGE.U è previsto essere elevato tra 3 anni

This company listing is no longer active

BiomX Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

BiomX Inc. to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

Biomx Inc. to Present Positive Phase 1B/2A Clinical Trial Data for Bx004 At the European Respiratory Society (Ers) Congress 2024

BiomX Announces NYSE American Acceptance of Plan to Regain Listing Compliance

BiomX Inc., Annual General Meeting, Jul 09, 2024

BiomX Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BiomX Inc. to Report Q1, 2024 Results on May 21, 2024

Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board

BiomX Inc. announced delayed annual 10-K filing

BiomX Inc. announced that it has received $50.013969 million in funding from Deerfield Management Company, LLC, AMR Action Fund GP, LLC, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, OrbiMed Advisors LLC

BiomX Inc. announced that it expects to receive $50.013969 million in funding

BiomX Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Biomx Announces Positive Topline Results from Part 2 of the Phase 1B/2A Trial Evaluating Bx004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Biomx to Present Data from Ongoing Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis

BiomX Inc. Announces the Appointment of Edward L. Williams to its Board of Directors

BiomX Inc. Announces Completion of Patient Dosing in Part 2 of Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Biomx Inc. to Present Part 1 Data from Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session At The46th European Cystic Fibrosis Conference

Biomx Inc. Appoints Jason M. Marks and Michael E. Dambach to the Board of Directors

BiomX Inc. Announces Board Resignations

BiomX Inc. Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease

BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange

BiomX Inc. Announces Dosing of the First Two Patients in Phase 1B/2A Study of Bx004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

BiomX Inc., Annual General Meeting, Aug 24, 2022

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita